Prophylactic compression sleeves after axillary lymph-node dissection

MS-N133 · Supportive care · Human evidence · Appraised 25 October 2026

Do prophylactic compression sleeves prevent arm swelling or lymphedema after axillary lymph-node dissection for breast cancer?

Evidence at a glance

Evidence label: Mixed evidence; a fitted sleeve may reduce early swelling in selected high-risk patients, but durable prevention is uncertain
Benefit: One 307-participant randomized trial reported less arm swelling over the first year, while another trial of early subclinical swelling found no statistically clear reduction in lymphedema progression.
Certainty: Low to moderate because populations, triggers, pressures, adherence and lymphedema definitions differ, and longer-term evidence is inconsistent.
Risk: An incorrect fit can cause pain, numbness, skin injury or constriction; a sleeve is not a substitute for diagnosis of new swelling.

What was studied

Population and design: A 2022 randomized trial enrolled 307 women after axillary lymph-node dissection. Standard exercise was compared with two fitted compression sleeves worn until three months after adjuvant treatment. Arm swelling was assessed by bioimpedance and relative arm-volume increase.

Contrasting trial: The PLACE trial randomized 143 women with early mild-to-moderate swelling after axillary clearance to a sleeve or no sleeve and followed progression. These are related but not identical prevention questions.

What the evidence found

In the 307-participant trial, sleeve use delayed arm swelling: hazard ratio 0.61 (95% CI 0.43–0.85) by bioimpedance and 0.56 (95% CI 0.33–0.96) by relative arm volume. At one year, arm-volume swelling was 14% with sleeves versus 25% with exercise alone; quality-of-life change did not differ meaningfully.

In PLACE, 24-month lymphedema rates were 30% with a sleeve and 41% without one (P=.32), and five-year progression was not reduced. Thirty-two control participants later received sleeves, complicating separation. A 2025 systematic review described preventive benefit as inconsistent.

How to interpret it

Sleeves are not a universal guarantee against lymphedema. The favorable trial began immediately after surgery in a high-risk population; PLACE intervened after early swelling. Different definitions and crossovers limit direct comparison. This evidence concerns swelling control, not recurrence or survival.

Practical safety context

Fitting should be done by a trained clinician. Remove the sleeve and seek advice for new pain, color change, numbness, tingling, skin breakdown or worsening swelling. New unilateral swelling also needs evaluation for infection, thrombosis or cancer-related obstruction.

Questions for the care team

Am I high risk enough that a prophylactic sleeve is reasonable?
What pressure, fit, daily wear time and replacement schedule match the evidence?
How will baseline and follow-up arm measurements be taken consistently?

Funding and conflicts

The positive 307-participant trial disclosed research funding involving SIGVARIS AG for an author, which matters when interpreting a garment study. PLACE was publicly funded; crossover and adherence complicate its estimate.

Sources

Last literature search: 25 October 2026. Record appraisal: 25 October 2026. This page is educational and does not replace individualized medical advice. Symptom or function improvement must not be interpreted as evidence of tumor response, delayed recurrence or longer survival.